A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Clinical trial NCT05200364 · TERMINATED

Trial details

NCT number: NCT05200364
Sponsor: Sutro Biopharma, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Ovarian Cancer Ovarian Carcinoma Ovary Cancer Fallopian Tube Cancer Primary Peritoneal Carcinoma

Start date: 2022-03-22
Primary completion: 2025-06-01
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.